Research by topic

Autonomic dysfunction is among the most consistently reported abnormalities in ME/CFS. Studies document heart rate variability impairments, orthostatic intolerance, postural orthostatic tachycardia syndrome (POTS), and abnormal blood pressure regulation across patient populations. These findings reflect dysregulation of the autonomic nervous system — the network governing heart rate, blood pressure, and circulatory response to positional change. Research explores links between autonomic dysfunction, endothelial dysfunction, vascular tone, and impaired cerebral blood flow, suggesting a systemic vascular component to ME/CFS pathophysiology.

Identifying reliable biomarkers for ME/CFS is a major research priority. Studies have explored cytokine profile differences, altered gene expression patterns, metabolomics signatures, autoantibodies against G-protein coupled receptors, and blood-based indicators from immune-system and energy-metabolism research. Multi-omics approaches — combining proteomics, transcriptomics, and metabolomics — have shown promise in identifying patient subgroups and distinguishing ME/CFS from other conditions. A reliable diagnostic biomarker would address one of the most significant clinical challenges in ME/CFS: the absence of an objective laboratory test for diagnosis.

Severe and very severe ME/CFS leaves patients largely or completely housebound or bedbound. This population is critically under-represented in research because of the real barriers severe illness creates — inability to travel to study sites, tolerate assessment protocols, or withstand sensory stimulation. As a result, most findings summarised across the atlas are drawn from samples that under-include the most affected patients.

Long COVID — also called post-acute sequelae of SARS-CoV-2 (PASC) — shares substantial clinical overlap with ME/CFS, including post-exertional malaise, fatigue, cognitive impairment, and autonomic abnormalities such as orthostatic intolerance. A subset of Long COVID patients meet formal diagnostic criteria for ME/CFS. Research explores shared mechanisms including immune-system abnormalities, viral persistence, microbiome disruption, and autonomic nervous system impairment. These mechanisms remain under investigation and are not fully settled. Understanding this overlap has strengthened the case for the broader category of post-infectious illness and brought new research attention to mechanisms that have been studied in ME/CFS for decades.

Unrefreshing sleep is a core feature of ME/CFS, reported by nearly all patients. Despite spending adequate or even excessive time in bed, patients consistently wake feeling unrestored. Sleep studies have documented abnormalities in sleep architecture, though these findings are not always consistent across studies.

Cognitive dysfunction — commonly described as brain fog — is one of the most disabling and frequently reported symptoms of ME/CFS. It affects memory, concentration, word retrieval, and processing speed. Cognitive exertion can trigger PEM, making sustained mental activity dangerous for many patients.

Alterations in the gut microbiome have been reported in ME/CFS patients, with differences in bacterial diversity and composition compared to healthy controls. The gut-immune axis is a plausible pathway through which microbiome changes could influence systemic symptoms, though causal evidence remains limited.

Chronic pain is reported by a majority of ME/CFS patients, including headaches, muscle pain, joint pain, and widespread tenderness. Central sensitization — an amplification of pain signals by the nervous system — may contribute. The overlap with fibromyalgia is substantial, though the two conditions are considered distinct.

There is currently no approved cure or disease-modifying treatment for ME/CFS. Management focuses on symptom relief and avoiding PEM triggers. Several pharmacological and non-pharmacological interventions have been studied, with mixed or limited results. Pacing remains the most widely recommended self-management strategy.

ME/CFS diagnosis has historically been complicated by inconsistent and sometimes conflicting case definitions. The Fukuda 1994 criteria, Oxford criteria, Canadian Consensus Criteria (CCC), International Consensus Criteria (ICC), and IOM/SEID 2015 criteria differ substantially in their requirements — particularly regarding post-exertional malaise, which is required by CCC, ICC, and IOM but not by Fukuda or Oxford. Research increasingly demonstrates that case definition quality shapes research findings, with studies using strict PEM-required criteria identifying a more homogeneous patient population and more consistent biomedical findings. The atlas classifies each study by the case definition used.

The hypothalamic-pituitary-adrenal (HPA) axis has been extensively studied in ME/CFS. Patterns suggestive of HPA-axis alterations have been reported in multiple studies — including mild hypocortisolism, attenuated diurnal cortisol variation, enhanced negative feedback, and blunted HPA-axis responsiveness — though findings are not uniform across cohorts. These neuroendocrine signals are associated with worse symptoms and poorer treatment outcomes in some clinical studies. HPA-axis alterations may reflect adjustments at the level of the central nervous system, the adrenal cortex, or both, and may interact with the immune and autonomic abnormalities reported in the illness.